Leveraging CAR T-Cell Combinations to Overcome Nonresponse and Relapse
  • CME
  • CE

New clinical data are emerging on combining CAR T-cell therapy with checkpoint inhibitors. Here’s my take on the potential of this strategy to improve outcomes in patients who relapsed or never responded to CAR T-cell monotherapy.
person default
Caron A. Jacobson, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: September 10, 2019 Expiration: September 9, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe current research on CAR T-cell therapy combinations to combat treatment resistance

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Celgene Corporation
Gilead Sciences

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Caron A. Jacobson, MD

Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Caron A. Jacobson, MD, has disclosed that she has received consulting fees from Celgene, Humanigen, Kite, Novartis, Pfizer, and Precision BioSciences.

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with leukemia, lymphoma, and/or myeloma.

Goal

The goal of this activity is to improve participants’ knowledge of and competence in leveraging CAR T-cell therapies to individualize clinical management of patients with B-cell malignancies: leukemias, lymphomas, and myeloma.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour.

Pharmacist Continuing Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-19-034-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 10, 2019, through September 09, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary from Farrukh Awan, MD, on the updated CCO online treatment decision support tool for CLL based on recent therapeutic advances

Farrukh T. Awan, MD Released: November 13, 2019

In this downloadable slideset, you can review the most recent clinical data on novel BCMA-targeted agents in the treatment of multiple myeloma.

Noopur Raje, MD Released: November 12, 2019

Expert-authored, CME-certified online educational activity covering the most recent clinical data on BCMA-targeted agents for treating multiple myeloma

Noopur Raje, MD Physicians: maximum of 0.8 AMA PRA Category 1 Credits Released: November 12, 2019 Expiration: November 11, 2020

In this slideset from Clinical Care Options, experts provide insights on the use of first-line systemic therapy for advanced HCC.

Richard Finn, MD Released: November 10, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?